natgillin/translations-raw huggingface dataset:
Most events were mild or moderate and did not limit study treatment.
Većina događaja bili su blagi ili umjereni i nisu ograničili liječenje u okviru ispitivanja.
Torre Realia, Plaza de Europa, 41-43 08908 L'Hospitalet de Llobregat Barcelona
Torre Realia, Plaza de Europa, 41-43 08908 L'Hospitalet de Llobregat
Some cases had more than one event of intestinal obstruction.
Neki su slučajevi imali više od jednog događaja opstrukcije crijeva.
Talk to your doctor or pharmacist before taking Xermelo:
Obratite se svom liječniku ili ljekarniku prije nego uzmete Xermelo:
You should tell your doctor about every medicine.
Trebate reći liječniku za svaki lijek koji uzimate.
The majority of intestinal obstruction events were serious (56 cases) and 33 cases were medically confirmed.
Većina događaja opstrukcije crijeva bila je ozbiljna (56 slučajeva), a 33 slučaja medicinski su potvrđena.
LP-951757 was pharmacologically inactive at TPH1 in vitro.
LP-951757 je bio farmakološki neaktivan kod TPH1 in vitro.
Tell your doctor straight away if you notice any of the following signs and symptoms that suggest that your liver may not be working properly:
Odmah obavijestite liječnika ako opazite neki od sljedećih znakova i simptoma koji ukazuju na to da Vam jetra možda ne radi pravilno:
• Swelling (build-up of fluid in the body)
• oticanje (nakupljanje tekućine u tijelu)
Most patients (92.1%) had fewer than 4 BM per day and all except 9 were treated by SSA therapy.
Većina bolesnika (92,1%) imala je manje od 4 pražnjenja crijeva na dan, a svi osim njih 9 bili su liječeni terapijom SSA-om.
This is because Xermelo can affect the way some other medicines work, or other medicines can affect the way Xermelo works.
To je potrebno zbog toga što Xermelo može utjecati na način na koji djeluju neki drugi lijekovi ili drugi lijekovi mogu utjecati na način na koji djeluje Xermelo.
• You should keep having injections of somatostatin analogues (lanreotide or octreotide) when taking
• Potrebno je nastaviti s injekcijama analoga somatostatina (lanreotid ili oktreotid) dok uzimate
The carcinogenic potential of telotristat etiprate was studied in transgenic mice (26 weeks) and rats (104 weeks).
Kancerogeni potencijal telotristatetiprata ispitivan je na transgeničnim miševima (26 tjedana) i štakorima (104 tjedna).
The tablets are packaged in a PVC/PCTFE/PVC/Al blister.
Tablete su pakirane u PVC/PCTFE/PVC/Al blisterima.
The maximum dose of Xermelo is 750 mg in 24 hours.
Najveća doza lijeka Xermelo iznosi 750 mg u razdoblju od 24 sata.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala, reproduktivne i razvojne toksičnosti.
Monitoring for suboptimal efficacy is recommended.
Preporučuje se praćenje zbog moguće suboptimalne djelotvornosti.
• Your doctor may carry out blood tests before you start taking this medicine and while you are taking it.
• Liječnik će Vam možda provesti pretrage krvi prije nego što počnete uzimati ovaj lijek, i provoditi ih dok ga uzimate.
• Depression, you may experience decreased self-esteem, lack of motivation, sadness or low mood
• depresija, možete iskusiti osjećaj smanjenog samopoštovanja, nedostatak motivacije, tugu ili loše raspoloženje
Your doctor will prescribe this medicine if your diarrhoea is not well controlled with injections of other medicines called ‘somatostatin analogues' (lanreotide or octreotide).
Liječnik će Vam propisati ovaj lijek ako proljev koji imate nije dobro kontroliran injekcijama drugih lijekova koji se nazivaju „analozi somatostatina“ (lanreotid ili oktreotid).
Your doctor will also monitor your liver.
liječnik će Vam pratiti rad jetre.
A cumulative search identified 62 relevant cases some of which with a close temporal relationship with the initiation of treatment with telotristat.
Kumulativnom pretragom identificirano je 62 relevantna slučaja, od kojih su neki bili u bliskoj vremenskoj povezanosti s početkom liječenja telotristatom.
Do not stop taking Xermelo without talking with your doctor.
Nemojte prestati uzimati Xermelo a da se prije niste posavjetovali s liječnikom.
In a phase 3 study of similar design (TELECAST), a total of 76 patients were evaluated for efficacy.
U ispitivanju faze 3 sličnog dizajna (TELECAST), djelotvornost je procijenjena u ukupno 76 bolesnika.
The clinical significance of the decrease in brain 5-HIAA with or without a concomitant decrease in brain 5-HT is unknown.
Klinička značajnost smanjenja 5-HIAA u mozgu s istodobnim smanjenjem 5-HT u mozgu ili bez njega nije poznata.
Your doctor will decide for how long you should take Xermelo.
Liječnik će odlučiti koliko dugo trebate uzimati Xermelo.
• if you have liver problems.
• ako imate tegoba s jetrom.
Therapy with telotristat should not be resumed unless the liver injury can be explained by another cause.
Terapija telotristatom ne smije se nastaviti osim ako oštećenje jetre nije moguće objasniti drugim uzrokom.
Following administration of 500 mg tid, the apparent terminal half-life was approximately 11 hours.
Nakon primjene doze od 500 mg TID, prividni terminalni poluvijek bio je približno 11 sati.
A total of 135 patients were evaluated for efficacy.
Djelotvornost je procijenjena u ukupno 135 bolesnika.
Moreover, in the long-term safety study (LX1606.1-302-CS), the incidence of depression was 21% and there is a probable biological mechanism that telotristat reduces the production of serotonin that may lead to symptoms of depression.
Štoviše, u ispitivanju dugoročne sigurnosti primjene telotristata (LX1606.1-302-CS) incidencija depresije bila je 21%, te postoji vjerojatan biološki mehanizam putem kojeg telotristat smanjuje proizvodnju serotonina, što može dovesti do simptoma depresije.
These have not been associated with concomitant elevations in total serum bilirubin.
Te povišene vrijednosti nisu bile povezane s istodobnim povišenjima ukupnog bilirubina u serumu.
The potential for in vivo drug interaction via inhibition of BCRP is considered low.
Potencijal za in vivo interakciju lijekova putem inhibicije BCRP-a smatra se niskim.
In rats, there were no adverse effects on male and female fertility.
U štakora nije bilo štetnih učinaka na plodnost mužjaka i ženki.
Therefore, intake of higher doses is not recommended (see section 5.2).
Stoga se ne preporučuje uzimanje viših doza (vidjeti dio 5.2).
Talk to your doctor or pharmacist:
Obratite se liječniku ili ljekarniku:
In phase 3 clinical trials, telotristat was routinely combined with loperamide with no evidence of safety concerns.
U kliničkim ispitivanjima faze III, telotristat se rutinski kombinirao s loperamidom bez dokaza da dovodi u pitanje sigurnost.
België/Belgique/Belgien, Luxembourg/Luxemburg
België/Belgique/Belgien, Luxembourg/Luxemburg Ipsen NV
If constipation develops, the use of telotristat and other concomitant therapies affecting bowel motility should be re-evaluated.
Ako se razvije konstipacija, potrebno je ponovno procijeniti primjenu telotristata i drugih istodobnih terapija koje utječu na motilitet crijeva.
Adverse reactions are listed by MedDRA body system organ class and by frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Nuspojave su navedene prema MedDRA-inoj klasifikaciji organskih sustava te prema učestalosti na temelju sljedećeg dogovora: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka ).
The mean Cmax, and AUC0-inf for the active metabolite, 1'-hydroxymidazolam, were also decreased by 34%, and 48%, respectively.
Srednje vrijednosti Cmax i AUC0-inf za aktivni metabolit, 1'-hidroksimidazolam, bile se također smanjene za 34% odnosno 48%.
Based on the small increase observed, clinically meaningful interactions with P-gp and MRP-2 substrates are unlikely.
Na temelju malog opaženog povećanja, klinički značajne interakcije sa supstratima P-gp-a i MRP-2 nisu vjerojatne.
The majority was eliminated in the faeces.
Veći dio eliminirao se stolicom.
Through inhibition of peripheral TPH1, telotristat reduces the production of serotonin, thus alleviating symptoms associated with carcinoid syndrome.
Inhibicijom perifernog TPH1 telotristat smanjuje proizvodnju serotonina, čime ublažava simptome povezane s karcinoidnim sindromom.
Your doctor will do blood tests to check your liver and will decide whether you should keep taking this medicine.
• Liječnik će Vam napraviti pretrage krvi kako bi provjerio rad jetre i prema tome će odlučiti smijete li nastaviti uzimati ovaj lijek.
This medicine works by reducing the amount of serotonin made by the tumour.
Ovaj lijek djeluje tako što smanjuje količinu serotonina koju tumor stvara.
Xermelo and these medicines reduce the number of your bowel movements and taken together, they can cause severe constipation.
Xermelo i ti lijekovi smanjuju broj pražnjenja crijeva i ako se uzimaju zajedno, mogu dovesti do teškog zatvora.
Management of overdose Treatment of an overdose should include general symptomatic management.
Zbrinjavanje predoziranja Liječenje predoziranja mora uključiti opće simptomatsko zbrinjavanje.
The tablets are white to off-white, film-coated and oval shaped.
Tablete su bijele do bjelkaste boje, obložene film-ovojnicom i ovalnog oblika.
Least Square mean difference 97.5% CL for difference p value
97,5% CL za razliku p-vrijednost
The recommended dose is one tablet (250 mg) three times a day.
Preporučena doza je jedna tableta (250 mg) tri puta na dan.
What Xermelo looks like and contents of the pack
Kako Xermelo izgleda i sadržaj pakiranja
Serotonin plays a critical role in regulating several major physiological processes, including secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-secreted in patients with carcinoid syndrome.
Serotonin ima ključnu ulogu u regulaciji nekoliko glavnih fizioloških procesa, uključujući sekreciju, motilitet, upalu i osjetljivost probavnog sustava, a u bolesnika s karcinoidnim sindromom se prekomjerno luči.
You should keep having injections of these other medicines when taking Xermelo.
Morate nastaviti primati injekcije tih lijekova i kada uzimate Xermelo.
Percentage of patients with durable responseb
Postotak bolesnika s postojanim odgovoromb
Since telotristat ethyl is rapidly converted to its active metabolite, which is > 25× more active than telotristat ethyl, no dose adjustments are required when using Xermelo with acid reducers.
Budući da se etiltelotristat brzo pretvara u svoj aktivni metabolit, koji je > 25× aktivniji od etiltelotristata, nije potrebna prilagodba doze kada se Xermelo koristi s lijekovima koji smanjuju želučanu kiselinu.
Patients should be advised to report any symptoms of depression, depressed mood and decreased interest to their physicians.
Bolesnicima treba savjetovati da obavijeste liječnika o svakom simptomu depresije, depresivnog raspoloženja i smanjenog interesa.
No decrease in brain 5-HT and 5-HIAA levels were observed after intravenous application of active metabolite.
Smanjenje razina 5-HT i 5-HIAA u mozgu nije opaženo nakon intravenske primjene aktivnog metabolita.
Laboratory monitoring of hepatic enzymes prior to and during telotristat therapy is recommended as clinically indicated.
Preporučuje se laboratorijsko praćenje jetrenih enzima prije i tijekom terapije telotristatom kako je klinički indicirano.
Taking into account the PRAC Assessment Report on the PSUR(s) for telotristat, the scientific conclusions of the CHMP are as follows:
Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za telotristat, znanstveni zaključci CHMP-a su sljedeći:
This might also be shown by changes in your blood test results, such as an increase of liver enzymes: gamma-glutamyl transferase (very common, may affect more than 1 in 10 people), transaminases and blood alkaline phosphatase (common, may affect up to 1 in 10 people).
To se može očitovati i promjenom u nalazima pretrage krvi, kao što je povećanje razina jetrenih enzima: gama-glutamil transferaze (vrlo često, može se pojaviti u više od 1 na 10 osoba), transaminaza i alkalne fosfataze u krvi (često, može se pojaviti u do 1 na 10 osoba).
Institut Produits Synthèse (IPSEN) AB Kista Science Tower Färögatan 33
Institut Produits Synthèse (IPSEN) AB Kista Science Tower
Telotristat induced CYP2B6 in vitro (see section 5.2).
Telotristat je inducirao CYP2B6 in vitro (vidjeti dio 5.2).
• medicines to treat depression, such as bupropion or sertraline.
• lijekove za liječenje depresije, kao što su bupropion ili sertralin
• Breathing problems, rapid heartbeat, fever, incontinence (uncontrollable urination), confusion, dizziness or agitation.
• problemi s disanjem, ubrzan rad srca, vrućica, inkontinencija (nekontrolirano mokrenje), zbunjenost, vrtoglavica ili uznemirenost.
QOL was generally stable over the course of the study.
Općenito, kvaliteta života bila je stabilna tijekom ispitivanja.
Xermelo is not recommended during pregnancy and in women of childbearing potential not using contraception.
Ne preporučuje se uzimati lijek Xermelo tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
Patients should not take a double dose to make up for a missed dose.
Bolesnici ne smiju uzeti dvostruku dozu kako bi nadoknadili propuštenu dozu.
Serious constipation was observed in 3 patients treated with a higher dose (500 mg) in the overall safety population (239 patients).
Ozbiljna konstipacija opažena je u 3 bolesnika liječena višim dozama (500 mg) u ukupnoj sigurnosnoj populaciji (239 bolesnika).
The adverse event was observed in clinical trials with frequency “very common” and is being reported from post-marketing setting.
Ovaj štetan događaj zabilježen je u kliničkim ispitivanjima s učestalošću „vrlo često“, a prijavljuje se i tijekom razdoblja nakon stavljanja lijeka u promet.
Patients should be monitored for signs and symptoms of constipation.
Bolesnike je potrebno pratiti zbog mogućih znakova i simptoma konstipacije.
Xermelo contains lactose (a type of sugar).
Xermelo sadrži laktozu (vrsta šećera).
Although patients with carcinoid syndrome may have a predisposition for depression, there were 38 post-marketing cases indicative of depression and depression-related events including two cases with positive dechallenge.
Iako bolesnici s karcinoidnim sindromom mogu imati predispoziciju za depresiju, nakon stavljanja lijeka u promet prijavljeno je 38 slučajeva koji ukazuju na depresiju i događaje povezane s depresijom, uključujući dva slučaja s povlačenjem nuspojave nakon prekida primjene lijeka (pozitivnim dechallenge-om).
The use of Xermelo is not recommended in patients with end-stage renal disease requiring dialysis (eGFR < 15 mL/min requiring dialysis) because efficacy and safety of Xermelo in these patients has not been established.
Uporaba Xermela se ne preporučuje u bolesnika s terminalnim stadijem bubrežne bolesti koji zahtijevaju dijalizu (eGFR <15 ml/min koji zahtijeva dijalizu) jer nije utvrđena djelotvornost i sigurnost Xermela u tih bolesnika.
The European Medicines Agency has waived the obligation to submit the results of studies with telotristat in all subsets of the paediatric population in the treatment of carcinoid syndrome (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka telotristata u svim podskupinama pedijatrijske populacije u liječenju karcinoidnog sindroma (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Administration of a single dose of 500 mg was well tolerated.
Primjena jedne doze od 500 mg dobro se podnosila.
• medicines used to treat high blood pressure, such as amlodipine.
• lijekove kojima se liječi visoki krvni tlak, kao što je amlodipin
This is because the medicine has not been tested in this age group.
To je zbog toga što lijek nije ispitan u toj dobnoj skupini.
Pack sizes of 90 and 180 tablets.
Veličine pakiranja od 90 i 180 tableta.
When the tumour releases too much serotonin into your bloodstream you can get diarrhoea.
Kada tumor otpušta previše serotonina u krvotok, može time uzrokovati proljev.
65 quai Georges Gorse 92100 Boulogne-Billancourt France
65 quai Georges Gorse 92100 Boulogne-Billancourt
Women of childbearing potential should be advised to use adequate contraception during treatment with telotristat.
Ženama reproduktivne dobi treba savjetovati da tijekom liječenja telotristatom koriste odgovarajuću kontracepciju.
This could mean that your doctor needs to change the dose(s) that you take.
To može značiti da Vam liječnik mora promijeniti dozu/doze koje uzimate.
Clinical signs were limited to increase in frequency of liquid faeces at all doses.
Klinički znakovi su bili ograničeni na veću učestalost tekućeg fecesa pri svim dozama.
Other medicines and Xermelo
Drugi lijekovi i Xermelo
Overall, severe to moderate renal impairment did not result in a clinically meaningful change in the PK profile or safety of telotristat ethyl and its metabolite telotristat.
Sveukupno, teška do umjerena oštećenja funkcije bubrega nisu dovela do klinički značajne promjene u farmakokinetičkom profilu ili sigurnosti etiltelotristata i njegovog metabolita telotristata.
There are no data from the use of telotristat in pregnant women.
Nema podataka o primjeni telotristata u trudnica.
• if you have end-stage kidney disease or are on dialysis.
• ako bolujete od bolesti bubrega u završnom stadiju ili ste na dijalizi.
For clinical management of elevated hepatic enzymes, see section 4.4.
Za kliničko zbrinjavanje povišenih jetrenih enzima vidjeti dio 4.4.
Prenatal development in rats and rabbits was affected by increased prenatal lethality (increased early and late resorptions), while no adverse effects were noted on postnatal development in rats.
U prenatalnom razvoju štakora i kunića pokazao se porast prenatalne smrtnosti (povećane rane i kasne resorpcije), dok u postnatalnom razvoju u štakora nisu opaženi štetni učinci.
They were generally of mild or moderate intensity.
Nuspojave su bile većinom blage ili umjerene jačine.
The only metabolite of telotristat (active metabolite) representing consistently > 10% of total plasma drug-related material was its oxidative decarboxylated deaminated metabolite, LP-951757.
Jedini metabolit telotristata (aktivni metabolit) koji u plazmi dosljedno čini > 10% ukupnog materijala povezanog s lijekom bio je njegov oksidativni dekarboksilirani dezaminirani metabolit, LP-951757.
Telotristat may have a small effect on your ability to drive or use any tools or machines.
Telotristat može imati mali učinak na Vašu sposobnost upravljanja vozilima ili rukovanja alatima ili strojevima.
The secondary objective of this study was to evaluate changes in patients' quality of life (QOL) through Week 84.
Sekundarni cilj ovog ispitivanja bila je procjena promjena u kvaliteti života bolesnika tijekom 84 tjedna.
• if you have signs of constipation, as telotristat reduces the number of your bowel movements.
• ako imate znakove zatvora, jer telotristat smanjuje broj pražnjenja crijeva.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „Rok valjanosti” i „EXP”.
The increases were largely reversible on dose interruption or reduction, or recovered whilst maintaining treatment at the same dose.
Povišenja su uglavnom bila reverzibilna kada je primjena doze privremeno prekinuta ili je doza smanjena, ili su se vrijednosti vratile na normalne vrijednosti kada se liječenje održavalo pri istoj dozi.
Beaufour Ipsen Industrie Rue Ethé Virton 28100 Dreux France
Beaufour Ipsen Industrie Rue Ethé Virton 28100 Dreux Francuska
Hepatic enzymes elevations
Povišenja jetrenih enzima
The efficacy and safety in patients with end-stage renal disease who require dialysis (eGFR < 15 mL/min/1.73 m² requiring dialysis) has not been established.
Djelotvornost i sigurnost u bolesnika s terminalnim stadijem bubrežne bolesti koji zahtijevaju dijalizu (eGFR < 15 ml/min/1,73 m² koji zahtijeva dijalizu) nisu utvrđene.
Number of Patients Percent Change at Week 12: Mean (SD) Estimate of Treatment Difference (95% CL)b
Postotak promjene u 12. tjednu: srednja vrijednost (SD) Procjena terapijske razlike (95% CL)
It is unknown whether telotristat ethyl and its metabolite are excreted in human breast milk.
Nije poznato izlučuju li se etiltelotristat i njegov metabolit u majčino mlijeko.
CL=confidence limit; tid=three times daily; SD=standard deviation; u5-HIAA = urinary 5--hydroxyindoleacetic acid.
CL = granica pouzdanosti; TID = tri puta na dan; SD = standardna devijacija; u5-HIAA = 5-hidroksiindoloctena kiselina u mokraći a.
Each tablet contains 168 mg of lactose (as anhydrous).
Jedna tableta sadrži 168 mg laktoze (bezvodne).
Patients should not breast-feed during telotristat treatment.
Bolesnice ne smiju dojiti tijekom liječenja telotristatom.
Ipsen Pharma GmbH Einsteinstraße 174
Deutschland, Österreich Ipsen Pharma GmbH Einsteinstraße 174
The pharmacokinetics of telotristat ethyl and its active metabolite have been characterised in healthy volunteers and patients with carcinoid syndrome.
Značajke farmakokinetike etiltelotristata i njegova aktivnog metabolita opisane su u zdravih dobrovoljaca i bolesnika s karcinoidnim sindromom.
The mean age was 63 years (range 35 to 84 years), 55% were male and 97% were white.
Srednja dob bila je 63 godine (raspon od 35 do 84 godine), 55% bolesnika bili su muškarci, a 97% bijelci.
Telotristat ethyl and telotristat have a low renal elimination following oral administration (less than 1% of the dose recovered from the urine).
Etiltelotristat i telotristat imaju nisku bubrežnu eliminaciju nakon peroralne primjene (manje od 1% doze dobivene iz urina).
Table 1 - Adverse reactions reported in patients treated with Xermelo System organ class
Tablica 1 - Nuspojave zabilježene u kliničkim ispitivanjima u bolesnika liječenih Xermelom Organski sustav
Ipsen Pharmaceuticals Ltd. Blanchardstown Industrial Park Blanchardstown IRL-Dublin 15
Blanchardstown Industrial Park Blanchardstown IRL-Dublin 15
The renal clearance of telotristat was 0.126 L/h.
Bubrežni klirens telotristata bio je 0,126 l/h.
These studies confirmed that telotristat did not increase the incidence of tumors in both species and sexes, at doses corresponding to an exposure of approximately 10- to 15-fold and 2- to 4.5-fold the human exposure to the active metabolite at the MRHD in mice and rats, respectively.
Ova ispitivanja potvrdila su da telotristat nije povećao incidenciju tumora u obje vrste i oba spola pri dozama koje su u miševa odgovarale izloženosti od približno 10 do 15 puta a u štakora približno 2 do 4,5 puta izloženosti aktivnom metabolitu u ljudi pri MRHD-u.
After oral administration to healthy volunteers, telotristat ethyl was rapidly absorbed, and almost completely converted to its active metabolite.
Nakon peroralne primjene u zdravih dobrovoljaca, etiltelotristat se brzo apsorbirao i gotovo potpuno pretvorio u svoj aktivni metabolit.
Depression, depressed mood
Psihijatrijski poremećaji depresija, depresivno raspoloženje
The long-term safety and tolerability of telotristat was evaluated in a nonpivotal (nonrandomized), phase 3, multicentre, open-label, long-term extension study.
Dugoročna sigurnost i podnošljivost telotristata procijenjena je u nepivotalnom (nerandomiziranom) multicentričnom, otvorenom dugoročnom nastavku ispitivanja faze 3.
Depressive disorders
Depresivni poremećaji
What Xermelo is and what it is used for 2.
Što je Xermelo i za što se koristi 2.
This medicine is used in adults with a condition called ‘carcinoid syndrome'.
Ovaj lijek se primjenjuje u odraslih osoba s „karcinoidnim sindrom”.